open access

Vol 51, No 3 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-09-01
Submitted: 2020-04-19
Get Citation

Efficacy of keratinocyte growth factor in prevention of oral mucositis in children undergoing allogeneic hematopoietic cell transplantation

Natalia Bartoszewicz, Krzysztof Czyżewski, Robert Dębski, Anna Krenska, Ewa Demidowicz, Monika Richert-Przygońska, Mariusz Wysocki, Jan Styczyński
DOI: 10.2478/ahp-2020-0030
·
Acta Haematol Pol 2020;51(3):172-178.

open access

Vol 51, No 3 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-09-01
Submitted: 2020-04-19

Abstract

Introduction

Oral mucositis is regarded by patients as one of the worst and debilitating complications of conditioning and hematopoietic cell transplantation (HCT). Prevention of mucositis is one of the priorities of supportive therapy during and after conditioning.

Objectives

The primary objective of the study was the analysis of efficacy of keratinocyte growth factor (KGF, palifermin) used in prophylaxis of oral mucositis in patients undergoing allo-HCT. The secondary objectives of the study included the analysis of the influence of palifermin on clinical course of oral mucositis and early transplant outcomes, as well as analysis of the contraindications of palifermin in patients undergoing allo-HCT.

Patients and methods

A total number of 253 allo-HCT performed between 2003 and 2018 in patients aged 0–19 years in a single center were analyzed. Overall, in 161 HCTs, palifermin was administered.

Results

Patients receiving KGF were transplanted earlier in the context of calendar year, and more often received ATG, mainly due to the higher rate of unrelated donor transplants. Allo-HCT patients who were administered palifermin had shorter time of mucositis (median: 9 vs. 13 days, < 0.001), lower mucositis grade (median: 2° vs. 3°; < 0.001), shorter period of total parenteral nutrition (median: 19 vs. 22 days; = 0.018), and lower incidence of episodes of febrile neutropenia (median: 39.1% vs. 83.1%; < 0.001).

Conclusions

The use of palifermin has decreased duration and severity of oral mucositis in children after allo-HCT. Palifermin is a safe and well-tolerated compound in children undergoing allo-HCT.

Abstract

Introduction

Oral mucositis is regarded by patients as one of the worst and debilitating complications of conditioning and hematopoietic cell transplantation (HCT). Prevention of mucositis is one of the priorities of supportive therapy during and after conditioning.

Objectives

The primary objective of the study was the analysis of efficacy of keratinocyte growth factor (KGF, palifermin) used in prophylaxis of oral mucositis in patients undergoing allo-HCT. The secondary objectives of the study included the analysis of the influence of palifermin on clinical course of oral mucositis and early transplant outcomes, as well as analysis of the contraindications of palifermin in patients undergoing allo-HCT.

Patients and methods

A total number of 253 allo-HCT performed between 2003 and 2018 in patients aged 0–19 years in a single center were analyzed. Overall, in 161 HCTs, palifermin was administered.

Results

Patients receiving KGF were transplanted earlier in the context of calendar year, and more often received ATG, mainly due to the higher rate of unrelated donor transplants. Allo-HCT patients who were administered palifermin had shorter time of mucositis (median: 9 vs. 13 days, < 0.001), lower mucositis grade (median: 2° vs. 3°; < 0.001), shorter period of total parenteral nutrition (median: 19 vs. 22 days; = 0.018), and lower incidence of episodes of febrile neutropenia (median: 39.1% vs. 83.1%; < 0.001).

Conclusions

The use of palifermin has decreased duration and severity of oral mucositis in children after allo-HCT. Palifermin is a safe and well-tolerated compound in children undergoing allo-HCT.

Get Citation

Keywords

hematopoietic cell transplantation; mucositis; palifermin; children

About this article
Title

Efficacy of keratinocyte growth factor in prevention of oral mucositis in children undergoing allogeneic hematopoietic cell transplantation

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 3 (2020)

Pages

172-178

Published online

2020-09-01

DOI

10.2478/ahp-2020-0030

Bibliographic record

Acta Haematol Pol 2020;51(3):172-178.

Keywords

hematopoietic cell transplantation
mucositis
palifermin
children

Authors

Natalia Bartoszewicz
Krzysztof Czyżewski
Robert Dębski
Anna Krenska
Ewa Demidowicz
Monika Richert-Przygońska
Mariusz Wysocki
Jan Styczyński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl